Biological and clinical implications of EGFR mutations in lung cancer

T Mitsudomi, T Kosaka, Y Yatabe - International journal of clinical …, 2006 - Springer
Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …
被引用次数：288 相关文章

[引用][C] Biological and clinical implications of EGFR mutations in lung cancer

T Mitsudomi, T Kosaka, Y Yatabe - International Journal of Clinical …, 2006 - cir.nii.ac.jp
Biological and clinical implications of EGFR mutations in lung cancer | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

Biological and clinical implications of EGFR mutations in lung cancer.

T Mitsudomi, T Kosaka, Y Yatabe - International Journal of Clinical …, 2006 - europepmc.org
Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Biological and clinical implications of EGFR mutations in lung cancer

T Mitsudomi, T Kosaka, Y Yatabe - International Journal of Clinical …, 2006 - infona.pl
Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Biological and clinical implications of EGFR mutations in lung cancer

T Mitsudomi, T Kosaka… - International Journal of …, 2006 - search.proquest.com
Background: Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Biological and clinical implications of EGFR mutations in lung cancer.

T Mitsudomi, T Kosaka… - International Journal of …, 2006 - search.ebscohost.com
Background. Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Biological and clinical implications of EGFR mutations in lung cancer

T Mitsudomi, T Kosaka… - International journal of …, 2006 - pubmed.ncbi.nlm.nih.gov
Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

[引用][C] Biological and clinical implications of EGFR mutations in lung cancer

M Tetsuya, K Takayuki, Y Yasushi - … of clinical oncology: official journal of …, 2006 - cir.nii.ac.jp
Biological and clinical implications of EGFR mutations in lung cancer | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …

Biological and clinical implications of EGFR mutations in lung cancer.

T Mitsudomi, T Kosaka… - International Journal of …, 2006 - search.ebscohost.com
Background. Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Biological and clinical implications of EGFR mutations in lung cancer

T Mitsudomi, T Kosaka, Y Yatabe - International Journal of Clinical …, 2006 - infona.pl
Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …